Real World Evidence Conference

Menu Back to Real-World-Evidence-Conference

Overview

November 6: Short Course
November 9-10: Conference

Real World Evidence (RWE) is increasingly becoming important for regulatory decision-making and beginning to touch all areas of the healthcare value chain. Historically used for post-market safety monitoring, sponsors are now beginning to use RWE to support clinical trial design and observational studies in order to generate better treatment approaches, while healthcare systems are collecting and using RWE to substantiate coverage decisions.

DIA’s Real World Evidence Conference will explore new and innovative applications of RWE, and deliver cutting-edge insights in how stakeholders are leveraging RWE to advance healthcare knowledge and decision-making.

Preconference Short Course

Introduction to Real World Data for Data Geeks

Who should attend?

Professionals from industry, academia, and government involved in all phases of the medical product lifecycle including:

Real World Evidence
Epidemiology
Policy
Regulatory Science
Technology development
Data analytics
Clinical Research

Learning objectives

At the completion of this forum, the participant should be able to:

Explain how RWE is being used today to inform biopharmaceutic development across product lifecycle
Describe the recent FDA strategic framework for RWD in regulatory decisions
Evaluate the future applications of RWE in drug development
Appraise how mobile technologies, AI, machine learning, and other technologies are being used to generate RWE
Evaluate how patient reported outcomes, EHR, and other patient data is expanding the resources for RWE
Discuss “lessons learned” from current uses of RWE, and how these can be applied for other future applications of RWE

Program Committee

Nancy A. Dreyer, PhD, MPH, FISPE •
IQVIA, United States
Steven A. Anderson, PhD • Director, Office of Biostatistics and Epidemiology, CBER
FDA, United States
Dorothee B. Bartels, PhD, MSc • Head of Global Real World Evidence and Digital Science
UCB Pharma, Belgium
Brian D. Bradbury, PhD, MA • Vice President, Center for Observational Research
Amgen, United States
Paul M. Coplan, DrSc, MBA, MSc, FISPE • Vice President, Medical Device Epidemiology & Real-World Data Analytics
Johnson & Johnson, United States
Marni Hall, PhD, MPH • Vice President, Clinical Evidence
IQVIA, United States
James Harnett, PharmD, MS • Executive Director, Health Economics & Outcomes Research
Regeneron Pharmaceuticals, Inc., United States
Jingyu (Julia) Luan, PhD • Regulatory Affairs Director, BioPharmaceuticals R&D, Late-Stage Development, CRM
AstraZeneca, United States
David Martin, MD, MPH • Vice President, Pharmacovigilance
Moderna, United States
Robert Reynolds, DrSc, FISPE • Vice President, Epidemiology & Patient-Centered Outcomes
GlaxoSmithKline, United States
Debra Schaumberg, DrSc, MPH • Vice President, Epidemiology & Head Strategic and Scientific Affairs
Evidera | PPD, United States
Mark Stewart, PhD • Vice President, Science Policy
Friends of Cancer Research, United States